ArticleBiomedical optics express2023
Identification of late-life depression and mild cognitive impairment via serum surface-enhanced Raman spectroscopy and multivariate statistical analysis.
Article in Biomedical optics express, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 4 citations in OpenAlex.
- Synergistic effects of surface-enhanced Raman spectroscopy and enzyme-linked immunoassays in diagnosis of Alzheimer's disease, mild cognitive impairment, and late-life depression.Frontiers in neurology · 2025Article
- Urine-based SERS and multivariate statistical analysis for identification of non-muscle-invasive bladder cancer and muscle-invasive bladder cancer.Analytical and bioanalytical chemistry · 2024Article
- Multi-branch attention Raman network and surface-enhanced Raman spectroscopy for the classification of neurological disorders.Biomedical optics express · 2024Article
- Advancing Brain Research through Surface-Enhanced Raman Spectroscopy (SERS): Current Applications and Future Prospects.Biosensors · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Identification of age-related neuropsychiatric disorders, i.e., late-life depression (LDD) and mild cognitive impairment (MCI) is of imperative clinical value considering the large probability of misdiagnosis and current lack of sensitive, non-invasive and low-cost diagnostic approaches. Here, the serum surface-enhanced Raman spectroscopy (SERS) technique is proposed to identify healthy controls, LDD and MCI patients. Based on SERS peaks analysis, abnormal levels of ascorbic acid, saccharide, cell-free DNA and amino acids in serum are found to be potential biomarkers for identifying LDD and MCI. These biomarkers might be related to oxidative stress, nutritional status, lipid peroxidation and metabolic abnormalities. Moreover, partial least square analysis-linear discriminant analysis (PLS-LDA) is applied to those collected SERS spectra. Finally, the overall identification accuracy is 83.2%, and accuracies are 91.6% and 85.7% for differentiating healthy versus neuropsychiatric disorders and LDD versus MCI, respectively. Thus, the serum SERS combined with multivariate statistical analysis has proved its successful potential for rapid, sensitive and non-invasive identification of healthy, LDD and MCI, which may open new avenues for early diagnosis and timely intervention for age-related neuropsychiatric disorders.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.